A new fluoroquinolone derivative exhibits inhibitory activity against human immunodeficiency virus type 1 replication

Chemotherapy

Volumn 45, Issue 1, 1999, Pages 48-55

  Kashiwase, Hiroto ^a   Momota, Kenji ^a   Ohmine, Toshinori ^a   Komai, Tomoaki ^a   Kimura, Tomio ^b   Katsube, Tetsushi ^b   Nishigaki, Takashi ^a   Kimura, Satoshi ^c   Shimada, Kaoru ^d   Furukawa, Hidehiko ^a  

^a DAIICHI SANKYO CO   (Japan)

^b UBE INDUSTRIES LTD   (Japan)

^c UNIVERSITY OF TOKYO   (Japan)

^d Tokyo Senbai Hospital   (Japan)

Author keywords

Anti bacterial agent; Anti HIV agent; Fluoroquinolone derivative; Human immunodeficiency virus; Inhibitor of HIV replication; R 71762

Indexed keywords

9 FLUORO 3 FLUOROMETHYL 2,3 DIHYDRO 10 [4 (2 PYRIDYL) 1 PIPERAZINYL] 7 OXO 7H PYRIDO[1,2,3 DE][1,4]BENZOXAZINE 6 CARBOXYLIC ACID; CIPROFLOXACIN; ENOXACIN; LEVOFLOXACIN; NORFLOXACIN; OFLOXACIN; QUINOLINE DERIVED ANTIINFECTIVE AGENT; R 71762; UNCLASSIFIED DRUG;

ANTIVIRAL ACTIVITY; ARTICLE; CONTROLLED STUDY; CYTOPATHOGENIC EFFECT; HUMAN IMMUNODEFICIENCY VIRUS 1; NONHUMAN; PRIORITY JOURNAL; VIRUS REPLICATION;

ANTI-HIV AGENTS; ANTI-INFECTIVE AGENTS; BACTERIA; CYTOPATHOGENIC EFFECT, VIRAL; HIV-1; HUMANS; MICROBIAL SENSITIVITY TESTS; OFLOXACIN; TUMOR CELLS, CULTURED; VIRUS REPLICATION;

EID: 0032903126     PISSN: 00093157     EISSN: None     Source Type: Journal    
DOI: 10.1159/000007164     Document Type: Article

References (32)

1. De Clercq E: Antiviral therapy for human immunodeficiency virus infections. Clin Microbiol Rev 1995; 8:200-239.
2. + T cell homeostasis and function in advanced HIV disease. Science 1997;277:112-116.
3. Wong JK, Hezareh M, Günthard HF, Havlir DV, Ignacio CC, Spina CA, Richman DD: Recovery of replication-competent HIV despite prolonged suppression of plasma viremia. Science 1997;278:1291-1295.
4. Finzi D, Hermankova M, Pierson T, Carruth LM, Buck C, Chaisson RE, Quinn TC, Chadwick K, Margolick J, Bookmeyer R, Gallant J, Markowitz M, Ho DD, Richman DD, Siliciano RF: Identification of a reservoir for HIV-1 in patients on highly active antiretroviral therapy. Science 1997;278:1295-1300.
5. Hogg RS, O'Shaughnessy MV, Gataric N, Yip B, Craib K, Schechter MT, Montaner JSG: Decline in deaths from AIDS due to new antiretrovirals. Lancet 1997;349:1294.
6. Egger M, Hirschel B, Francioli P, Sudre P, Wirz M, Flepp M, Rickenbach M, Malinverni R, Vernazza P, Battegay M, the Swiss HIV Cohort Study: Impact of new antiretroviral combination therapies in HIV infected patients in Switzerland: Prospective multicentre study. BMJ 1997;315:1194-1199.
7. Mouton Y, Alfandari S, Valette M, Cartier F, Dellamonica P, Humbert G, Lang JM, Massip P, Machali D, Leclercq P, Modai J, Portier H, Fédération Nationale des Centres de Lutte contre le SIDA: Impact of protease inhibitors on AIDS-defining events and hospitalizations in 10 French AIDS reference centres. AIDS 1997;11:F101-F105.
8. Brodt HR, Kamps BS, Gute P, Knupp B, Staszewski S, Helm EB: Changing incidence of AIDS-defining illnesses in the era of antiretroviral combination therapy. AIDS 1997;11:1731-1738.
9. Palella FJ Jr, Delaney KM, Moorman AC, Loveless MO, Fuhrer J, Satten GA, Aschman DJ, Holmberg SD, the HIV Outpatient Study Investigators: Declining morbidity and mortality among patients with advanced human immunodeficiency virus infection. N Engl J Med 1998;338:853-860.
10. Kaufmann D, Pantaleo G, Sudre P, Telenti A: CD4-cell count in HIV-1-infected individuals remaining viraemic with highly active antiretroviral therapy (HAART). Lancet 1998;351:723-724.
11. Hirschel B, Francioli P: Progress and problems in the fight against AIDS. N Engl J Med 1998;338:906-908.
12. Perrin L, Telenti A: HIV treatment failure: Testing for HIV resistance in clinical practice. Science 1998;280: 1871-1873.
13. Chun TW, Stuyver L, Mizell SB, Ehler LA, Mican JAM, Baseler M, Lloyd AL, Nowak MA, Fauci AS: Presence of an inducible HIV-1 latent reservoir during highly active antiretroviral therapy. Proc Natl Acad Sci USA 1997;94:13193-13197.
14. Ho DD: Toward HIV eradication or remission: The tasks ahead. Science 1998;280:1866-1867.
15. Carr A, Samaras K, Burton S, Law M, Freund J, Chisholm DJ, Cooper DA: A syndrome of peripheral lipodystrophy hyperlipidaemia and insulin resistance in patients receiving HIV protease inhibitors. AIDS 1998;12:F51-F58.
16. Viraben R, Aquilina C: Indinavir-associated lipodystrophy. AIDS 1998;12:F37-F39.
17. Daudon M, Estépa L, Viard JP, Joly D, Jungers P: Urinary stones in HIV-1-positive patients treated with indinavir. Lancet 1997;349:1294-1295.
18. Lesher GY, Forelich ED, Gruet MD, Bailey JH, Brundage RP: 1,8-Naphthyridine derivatives. A new class of chemotherapeutic agents. J Med Pharm Chem 1962;5:1063-1068.
19. Koga H, Itoh A, Murayama S, Suzue S, Irikura T: Structure-activity relationships of antibacterial 6,7-and 7,8-disubstituted 1-alkyl-1,4-dihydro-4-oxoquinoline-3-carboxylic acids. J Med Chem 1980;23:1358-1363.
20. Mitscher LA, Devasthale P, Zavod R: Structure-activity relationships: in Hooper DC, Wolfson JS (ed): Quinolone Antimicrobial Agents, ed 2. Washington, American Society for Microbiology, 1993, pp 3-51.
21. Hooper DC, Wolfson JS: Mechanisms of quinolone action and bacterial killing; in Hooper DC, Wolfson JS (ed): Quinolone Antimicrobial Agents, ed 2. Washington, American Society for Microbiology, 1993, pp 53-75.
22. Chu DTW: The future role of quinolones. Exp Opin Ther Patents 1996; 6:711-737.
23. Nozaki-Renard J, Ino T, Sato Y, Marumoto Y, Ohta G, Furusawa M: Fluoroquinolones protect the human lymphocyte CEM cell line from HIV-1-mediated cytotoxicity. Cell Struct Funct 1990;15:295-299.
24. Nozaki-Renard J, Iino T, Sato Y, Marumoto Y, Ohta G, Furusawa M: A fluoroquinolone (DR-3355) protects human lymphocyte cell lines from HIV-1-induced cytotoxicity. AIDS 1990;4:1283-1286.
25. Gollapudi S, Kim CH, Roshanravan B, Gupta S: Ciprofloxacin inhibits activation of latent human immunodeficiency virus type 1 in chronically infected promonocytic U1 cells. AIDS Res Hum Retroviruses 1998;14:499-504.
26. Kimura T, Katsube T: Aminoquinolone derivatives as anti-HIV agents. Eur Patent 1993, EP0572259A1.
27. Pauwels R, Balzarini J, Baba M, Snoeck R, Schols D, Herdewijn P, Desmyter J, De Clercq E: Rapid and automated tetrazolium-based colorimetric assay for the detection of anti-HIV compounds. J Virol Methods 1988;20:309-321.
28. Scudiero DA, Shoemaker RH, Paull KD, Monks A, Tierney S, Nofziger TH, Currens MJ, Seniff D, Boyd MR: Evaluation of a soluble tetrazolium/formazan assay for cell growth and drug sensitivity in culture using human and other tumor cell lines. Cancer Res 1988;48: 4827-4833.
29. National Committee for Clinical Laboratory Standards: Methods for Dilution Antimicrobial Susceptibility Tests for Bacteria That Grow Aerobically, ed 3. Villanova, National Committee for Clinical Laboratory Standards, 1993, vol 10, No 8.
30. Poli G, Orenstein JM, Kinter A, Folks TM, Fauci AS: Interferon-α but not AZT suppresses HIV expression in chronically infected cell lines. Science 1989;244:575-577.
31. Mitsuya H, Broder S: Strategies for antiviral therapy in AIDS. Nature 1987;325:773-778.
32. Baba M, Okamoto M, Makino M, Kimura Y, Ikeuchi T, Sakaguchi T, Okamoto T: Potent and selective inhibition of human immunodeficiency virus type 1 transcription by piperazinyloxoquinoline derivatives. Antimicrob Agents Chemother 1997;41:1250-1255.